Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Zymeworks Inc (ZYME)

17.7 0.69 (4.06%)

05-21 16:02

Open:

17.27

Pre. Close:

17.01

High:

17.97

Low:

17.01

Volume:

83,297

Market Cap:

454M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

17.987 - 18.074

18.074 - 18.149

Low:

16.808 - 16.905

16.905 - 16.99

Close:

17.55 - 17.705

17.705 - 17.839

Technical analysis  (as of: 2018-05-21 4:35:11 PM)

Overall:

      

Stoxline posted a BUY today, upgraded from lower rating. This stock seems to be ready for a new bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, a new upward move is expected.

Target:

Six months: 21.02     One year: 24.56

Support:

Support1: 14.07    Support2: 11.64

Resistance:

Resistance1: 18.00    Resistance2: 21.02

Pivot:

15.56

Moving Averages:

MA(5): 15.93     MA(20): 15.29

MA(100): 11.80     MA(250): 9.73

MACD:

MACD(12,26): 0.81     Signal(12,26,9): 0.87

%K %D:

%K(14,3): 59.35     %D(3): 61.36

RSI:

RSI(14): 59.80

52-Week:

High: 18  Low: 6.25  Change(%): 35.4

Average Vol(K):

3-Month: 4090  10-Days 8636

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
ZYME has closed below upper band by 11.8%. Bollinger Bands are 72.5% wider than normal. The large width of the bands suggest high volatility as compared to ZYME's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue.

Headline News

2018-05-15T06:55:49-04:00
Zymeworks expands I-O collaboration with Daiichi Sankyo

2018-05-14T17:00:00-04:00
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies

2018-05-10T16:30:00-04:00
Zymeworks to Present at the UBS Global Healthcare Conference 2018

2018-05-04T05:00:00-04:00
Actinium Pharmaceuticals: Neglected Assets In Niche Oncology

2018-05-01T16:05:00-04:00
Zymeworks Reports 2018 First Quarter Financial Results

2018-04-30T16:05:00-04:00
Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2018

2018-04-25T06:00:00-04:00
Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

2018-04-23T16:21:57-04:00
Zymeworks up 15% after hours on expanded Celgene partnership

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

25.46

Shares Float (M)

25.46

% Held by Insiders

% Held by Institutions

36.20

Shares Short (K)

34

Shares Short Prior Month (K)

Stock Financials

EPS

-0.830

EPS Est. Current Year

-2.980

EPS Est. Next Year

-2.540

EPS Est. Next Quarter

-0.670

Forward EPS

-2.309

Book Value (p.s.)

3.860

PEG Ratio

Profit Margin

-32.85

Operating Margin

-14.42

Return on Assets (ttm)

-16.5

Return on Equity (ttm)

-38.0

Qtrly Rev. Growth

2143.3

Gross Profit (p.s.)

-0.721

Sales Per Share

EBITDA (p.s.)

-0.999

Qtrly Earnings Growth

Operating Cash Flow (M)

0.22

Levered Free Cash Flow (M)

-2.54

atoplab.com

Valuation

P/E

-21.33

P/E Growth Ratio

0.52

P/BV

4.59

P/S

183818864.00

P/CF

2058.09

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.